Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Sean Clouston In a recent study of 35 World Trade Center first responders in the Journal of Alzheimer’s Disease, lead author Sean Clouston, who is a Professor in the Department of Family, Population ...

Aside from the potential curse of long COVID, people who've had the SARS-CoV-2 virus may be more likely to develop high ...

In ‘Doctored’, Charles Piller, a science journalist, details how groupthink and dishonesty steered Alzheimer’s research off ...

A new study reveals that tau protein affects memory, while beta-amyloid disrupts emotions in Alzheimer’s disease. Using a novel mouse model, researchers found that both proteins interact to worsen ...

A new study suggests that getting more than six hours of good-quality sleep each night may help slow down or even prevent the ...

There is no cure. Between 1995 and 2021, around $42bn was poured into more than 1,000 clinical trials. Yet only a handful of ...

AD neuropathology is due to the progressive deposition of extracellular amyloid-beta (Aβ) peptide and intracellular hyperphosphorylated tau protein. The accumulated Aβ forms amyloid plaques, while the ...

An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...

This accumulation could elevate their risk of developing late-onset amyloid-related disorders, such as Alzheimer’s disease.